Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.

Autor: Ansuinelli M; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Della Starza I; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.; GIMEMA Foundation, Rome, Italy., Lauretti A; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Elia L; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Siravo V; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Messina M; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., De Novi LA; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Taherinasab A; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Canichella M; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Guarini A; Department of Molecular Medicine, Sapienza University, Rome, Italy., Foà R; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Chiaretti S; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Jazyk: angličtina
Zdroj: Hematological oncology [Hematol Oncol] 2021 Dec; Vol. 39 (5), pp. 680-686. Date of Electronic Publication: 2021 Aug 16.
DOI: 10.1002/hon.2913
Abstrakt: In Ph+ acute lymphoblastic leukaemia (Ph+ ALL), minimal residual disease (MRD) is the most relevant prognostic factor. Currently, its evaluation is based on quantitative real-time polymerase chain reaction (Q-RT-PCR). Digital droplet PCR (ddPCR) was successfully applied to several haematological malignancies. We analyzed 98 samples from 40 Ph+ ALL cases, the majority enrolled in the GIMEMA LAL2116 trial: 10 diagnostic samples and 88 follow-up samples, mostly focusing on positive non-quantifiable (PNQ) or negative samples by Q-RT-PCR to investigate the value of ddPCR for MRD monitoring. DdPCR BCR/ABL1 assay showed good sensitivity and accuracy to detect low levels of transcripts, with a high rate of reproducibility. The analysis of PNQ or negative cases by Q-RT-PCR revealed that ddPCR increased the proportion of quantifiable samples (p < 0.0001). Indeed, 29/54 PNQ samples (53.7%) proved positive and quantifiable by ddPCR, whereas 13 (24.1%) were confirmed as PNQ by ddPCR and 12 (22.2%) proved negative. Among 24 Q-RT-PCR-negative samples, 13 (54.1%) were confirmed negative, four (16.7%) resulted PNQ and seven (29.2%) proved positive and quantifiable by ddPCR. Four of 5 patients, evaluated at different time points, who were negative by Q-RT-PCR and positive by ddPCR experienced a relapse. DdPCR appears useful for MRD monitoring in adult Ph+ ALL.
(© 2021 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: